Breakthrough Therapy Designation
Psilocybin Therapy
The active compound in "magic mushrooms," psilocybin is being studied for depression, anxiety, and end-of-life distress. It received FDA Breakthrough Therapy Designation for treatment-resistant depression.
50Clinical Trials
3Companies
6Legal States
FDA StatusBreakthrough Therapy Designation
Legal PathwayState-by-state regulation (OR, CO, NM)
Also Known Asmagic mushrooms, COMP360, psilocin
Legal Status by State
View full legal tracker →Fully Operational
Legal, Launching
Decriminalized
Active Legislation
Research Only
No Activity
Legal & Regulated4
AZCONMOR
Decriminalized2
DCMI
Pending Legislation11
AKCACTGAMANVNJNYTXVTWA
Clinical Trials
Phase 122
Phase 217
Phase 33
Active, Not Recruiting·N/A·psilocybin
Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism
Healing Advocacy Fund
Alcohol Use Disorder
Active, Not Recruiting·Phase 2·psilocybin
Psilocybin for Treatment-Resistant Depression
University of Colorado, Denver
Major Depressive DisorderAnhedoniaTreatment Resistant Depression
Active, Not Recruiting·Phase 1·psilocybin
A Study of Psilocybin for PTSD
Johns Hopkins University
Post Traumatic Stress Disorder
Active, Not Recruiting·Phase 2·psilocybin
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
Advanced CancerStage IV Solid Tumor CancerStage IV Sarcoma of Bone+3 more
Active, Not Recruiting·Phase 3·psilocybin
Psilocybin for Major Depressive Disorder (MDD)
Usona Institute
Depressive Disorder, Major
Active, Not Recruiting·Phase 2·psilocybin
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder
Peggy C Nopoulos
Alcohol Use Disorder
Companies & Research
Organizations developing Psilocybin-based therapies